Using pharmacogenetics in real time to guide warfarin initiation: a clinician update

Circulation. 2011 Dec 6;124(23):2554-9. doi: 10.1161/CIRCULATIONAHA.111.019737.
No abstract available

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Anticoagulants / administration & dosage*
  • Anticoagulants / adverse effects
  • Aryl Hydrocarbon Hydroxylases / genetics
  • Atrial Fibrillation / complications*
  • Atrial Fibrillation / genetics
  • Cytochrome P-450 CYP2C9
  • Female
  • Humans
  • Mixed Function Oxygenases / genetics
  • Pharmacogenetics / methods*
  • Precision Medicine / methods
  • Thrombosis / genetics
  • Thrombosis / prevention & control*
  • Vitamin K Epoxide Reductases
  • Warfarin / administration & dosage*
  • Warfarin / adverse effects

Substances

  • Anticoagulants
  • Warfarin
  • Mixed Function Oxygenases
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Vitamin K Epoxide Reductases